Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker IVVD
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 18.49M | 6.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Joseph Edelman | 18.49M | 6.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Perceptive Advisors LLC | 18.49M | 6.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Mark N. Lampert | 29.57M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF Inc/Il | 29.57M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF Partners L P/Il | 29.57M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF GP Holdings LLC | 27.22M | 9.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF Partners OS Ltd. | 1.89M | 0.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Biotechnology Value Trading Fund OS LP | 1.89M | 0.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF II GP LLC | 11.18M | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Biotechnology Value Fund II LP | 11.18M | 3.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF I GP LLC | 16.03M | 5.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Biotechnology Value Fund L P | 16.03M | 5.4% | SCHEDULE 13G/A ↗ |
| Jul 28, 2026 | SCHEDULE 13G | IVVD Invivyd, Inc. | BlackRock, Inc. | 16.12M | 5.5% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | RA Capital Healthcare Fund, L.P. | 21.34M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Rajeev Shah | 21.34M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Peter Kolchinsky | 21.34M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | RA Capital Management, L.P. | 21.34M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Steven A. Cohen | 43,931 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Point72 Capital Advisors, Inc. | 43,931 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Point72 Asset Management, L.P. | 43,931 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | RA Capital Healthcare Fund, L.P. | 28.86M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Rajeev Shah | 28.86M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Peter Kolchinsky | 28.86M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | RA Capital Management, L.P. | 28.86M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Mark N. Lampert | 25.52M | 9.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF Inc/Il | 25.52M | 9.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF Partners L P/Il | 25.52M | 9.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF GP Holdings LLC | 23.57M | 8.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF Partners OS Ltd. | 1.56M | 0.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Biotechnology Value Trading Fund OS LP | 1.56M | 0.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF II GP LLC | 9.95M | 3.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Biotechnology Value Fund II LP | 9.95M | 3.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | BVF I GP LLC | 13.62M | 4.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Biotechnology Value Fund L P | 13.62M | 4.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Steven A. Cohen | 16.65M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Point72 Capital Advisors, Inc. | 16.65M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Point72 Asset Management, L.P. | 16.65M | 6.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Lee S. Ainslie III | 18.97M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Maverick Capital Management, LLC | 18.97M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Maverick Capital, Ltd. | 18.97M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Guy Levy | 7.71M | 2.8% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus GP, LLC | 7.71M | 2.8% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus Capital Management, L.P. | 7.71M | 2.8% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus Capital Group, LLC | 6.03M | 2.2% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus Capital, LLC | 6.03M | 2.2% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus Capital Master Fund, L.P. | 6.03M | 2.2% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus PE GP III, LLC | 1.68M | 0.6% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus Private Equity GP III, LLC | 1.68M | 0.6% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | IVVD Invivyd, Inc. | Soleus Private Equity Fund III, L.P. | 1.68M | 0.6% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances